KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Shares Outstanding (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Shares Outstanding for 11 consecutive years, with $96.0 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 11.98% to $96.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $96.0 million through Dec 2025, up 11.98% year-over-year, with the annual reading at $96.0 million for FY2025, 11.98% up from the prior year.
  • Shares Outstanding hit $95.9 million in Q4 2025 for CRISPR Therapeutics AG, up from $94.0 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $95.9 million in Q4 2025 to a low of $180316.0 in Q4 2021.
  • Historically, Shares Outstanding has averaged $54.9 million across 5 years, with a median of $78.4 million in 2022.
  • Biggest five-year swings in Shares Outstanding: tumbled 99.77% in 2023 and later surged 47225.68% in 2024.
  • Year by year, Shares Outstanding stood at $180316.0 in 2021, then surged by 43441.59% to $78.5 million in 2022, then tumbled by 99.36% to $500000.0 in 2023, then skyrocketed by 17048.4% to $85.7 million in 2024, then rose by 11.98% to $96.0 million in 2025.
  • Business Quant data shows Shares Outstanding for CRSP at $96.0 million in Q4 2025, $93.9 million in Q3 2025, and $88.4 million in Q2 2025.